Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $11.0 million.

  • Autolus Therapeutics' Accounts Payables rose 67341.33% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 67341.33%. This contributed to the annual value of $2.0 million for FY2024, which is 181165.05% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Accounts Payables of $11.0 million as of Q3 2025, which was up 67341.33% from $5.4 million recorded in Q2 2025.
  • Autolus Therapeutics' Accounts Payables' 5-year high stood at $11.0 million during Q3 2025, with a 5-year trough of -$783000.0 in Q3 2021.
  • In the last 5 years, Autolus Therapeutics' Accounts Payables had a median value of $1.1 million in 2021 and averaged $1.7 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Accounts Payables tumbled by 25352.94% in 2021, and later soared by 195507.25% in 2024.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Accounts Payables stood at $431000.0 in 2021, then grew by 23.2% to $531000.0 in 2022, then crashed by 80.6% to $103000.0 in 2023, then skyrocketed by 1811.65% to $2.0 million in 2024, then soared by 456.98% to $11.0 million in 2025.
  • Its last three reported values are $11.0 million in Q3 2025, $5.4 million for Q2 2025, and $4.5 million during Q1 2025.